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We report a novel mutation detected in a 33 year old Chinese man with congenital bilateral absence of the vas deferens (CBAVD), a past
history of pulmonary meliodosis infection and a past history of bronchiolitis obliterans organising pneumonia.
A novel splice site mutation in intron 6b (1001+5 G→A) in the homozygous state was identified, and was predicted to lead to inefficient
splicing. He was also homozygous at all intragenic and flanking polymorphic markers. Quantitative realtime PCR analysis showed that there
were 2 copies of the CFTR gene present, ruling out the possibility of a deletion, and strongly suggesting the possibility of uniparental
isodisomy involving at least a part of chromosome 7.
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pneumonia; Meliodosis; MutationThe patient was a 33 year old Chinese man who presented
to our hospital for the problem of primary infertility. The
cause was identified as congenital bilateral absence of the
vas deferens (CBAVD) which was diagnosed at exploratory
surgery. The patient gave a history of having bronchiolitis
obliterans organizing pneumonia (BOOP) in 1989 that was
diagnosed by an open lung biopsy, and a history of pul-
monary meliodosis. He appeared to have recovered from
these episodes and had no pulmonary symptoms when seen
by us. There were no symptoms of growth failure or pan-
creatic insufficiency. His parents were nonconsanguineous
and he had three sisters; the eldest sister had infertility of
undetermined origin and his youngest sister was suspected to⁎ Corresponding author. Fax: +65 6779 7486.
E-mail address: paegohlm@nus.edu.sg (D.L.M. Goh).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2007.02.004have pulmonary meliodosis. There was no family history of
chronic lung disease or pancreatic insufficiency.
1. Material and methods
1.1. Sweat testing
Sweat was stimulated by pilocarpine iontophoresis using
the Webster sweat inducer and the sweat collected in a
microbore tubing (Wescor Macroduct, Wescor Inc., Logan,
USA). The sweat conductivitywasmeasured using theWescor
“Sweat-Chek” conductivity analyzer. Sweat conductivity
result greater than or equal to 60 mmol/L (equivalent sodium
chloride, NaCl) was considered positive.
1.2. DNA extraction
GenomicDNAwas extracted fromanti-coagulated blood using
conventional methods. DNAwas stored at 4 °C until analyzed.ed by Elsevier B.V. All rights reserved.
Table 1
Primers used in multiplex-PCR microsatellite analysis
Primer name Repeat Sequence (5′→3′) and fluorescent label Final concentration
D7S643F (CA)n AGCTAATATTGCTGCCTTTT 0.4 μM each
D7S643R FAM-CAATCTCTTGCTAGATGCCA
D7S2502F (AC)n HEX-CCAGTGGTTTTAGTCATTTGTTTTG 0.4 μM each
D7S2502R CATGTATGCTCATGGTTGGA
D7S2847F (TCTA)n TCACCTTCAGAAAGTATTGCC 0.2 μM each
D7S2847R FAM-TGAGGTGTTTCTCCAAGCTC
D7S486F (CA)n AAAGGCCAATGGTATATCCC 0.06 μM each
D7S486R FAM-GCCCAGGTGATTGATAGTGC
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The CFTR gene was amplified essentially as described by
Wong et al. [1], sequenced using the Big Dye terminator
cycle sequencing kit (Applied Biosystems), and analyzed on
an ABI 3100 Genetic Analyzer (Applied Biosystems). In this
paper, the original CFTR nucleotide numbering was used i.e.
nucleotide #1 is first nucleotide of exon 1.
1.4. Microsatellite analysis
Four microsatellite markers, two flanking each end of the
CFTR gene, were amplified in a single multiplex PCR reac-
tion and analyzed on the ABI 3100 Genetic Analyzer using
GeneScan™ and Genotyper™ software (Applied Biosys-
tems). Each multiplex PCR amplification was performed in a
final volume of 25μl containing 2 units ofHotStarTaq™DNA
polymerase in supplied buffer (Qiagen), 0.2 mM of each
dNTP, primers in concentrations as indicated in Table 1, and
50 ng of genomic DNA. Thermal cycling conditions were an
initial denaturation at 95 °C for 15 min, followed by 30 cycles
of 94 °C for 30 s, 55 °C for 75 s, and 72 °C for 30 s, endingwith
a final extension at 72 °C for 6 min.
1.5. Realtime PCR analysis
Quantitative realtime PCR analysis of 5′UTR, exon 22,
and 3′UTR fragments of CFTR to determine gene copy num-
ber relative to a control GAPDH gene fragment.. Each 20 μl
reaction was performed using the Quantitect™ SYBR Green
PCR reagent mix (Qiagen) with 0.5 μM each of forward andTable 2
Primers used in quantitative realtime PCR analysis
Fragment Primer 5′→3′ sequence Fragment
size (bp)
5′UTR Forward GACATCACAGCAGGTCAG 142
Reverse CCTTTTCCAGAGGCGACC
Exon 22 Forward GCTTTCAGAACTCCTGTG 335
Reverse TGTCACCATGAAGCAGGC
3′UTR Forward GGTACTTCAAATCCTTGAAG 140
Reverse GTTTCACTAGACAATAAGCTG
GAPDH Forward GAAGGTGAAGGTCGGAGTC 256
Reverse GAAGATGGTGATGGGATTTCreverse primer (Table 2) and 100 ng of genomic DNA.
Thermal cycling was performed on a Lightcycler™ (Roche),
with a 95 °C pre-incubation for 15 min, followed by 40
cycles of 94 °C for 15 s, 55 °C for 30 s, and 72 °C for 20 s.
Crossing point value for each CFTR fragment was nor-
malized against that for GAPDH. Normalized values for
each of the 3 CFTR fragments in the patient were then com-
pared against the corresponding normalized values from 5
unaffected Chinese DNAs. A patient to control ratio of ∼ 0.5
indicates heterozygosity for a deletion while a ratio of ∼ 1
indicates absence of deletion.
2. Results
We identified a splice site mutation in intron 6b (1001+
5 G→A) in the homozygous state in this patient. Analysis of
40 unaffected Chinese DNAs and an additional 44 cord
blood DNAs (14 Chinese, 14 Malay, and 16 Indian) showed
homozygous wildtype 1001+5 G, ruling out 1001+5 A as a
common polymorphism. Parental DNAs of the patient were
not available for analysis.
Interestingly, the patient was homozygous at every
intragenic polymorphic site that was analyzed. These were:
5′UTR nt125 (G/G), intron 3 nt405+46 SNP(T/T), intron 6a
nt876-31 (TTGA6/TTGA6), intron 8 nt1342-6(11TG7T/
11TG7T), intron 9 nt1525-61 (A/A), exon 10 nt1540 (G/G;
V470/V470), exon 14a nt1694 (T/T), and intron 20 nt4005+
121 (T6/T6). In marked contrast, none of the control DNAs
analyzed were homozygous at all with the intragenic poly-
morphic loci.
We also performed a PCR analysis of flanking micro-
satellite markers viz markers D7S2502 and D7S486 which
lie upstream of and centromeric to the CFTR gene, and mark-
ers D7S2847 and D7S643 which lie downstream of and
telomeric to CFTR. The results showed homozygosity for all
4 microsatellite markers D7S2502 (AC19/AC19) D7S486
(CA18/CA18) D7S2847 (TCTA8/TCTA8) and D7S643
(CA23/CA23). In contrast, none of 48 unrelated control
DNAs (16 Chinese, 16 Malay, 16 Indian) were homozygous
at all 4 markers.
To determine if these observations were due to a deletion,
quantitative realtime PCR analysis at the CFTR locus was
performed on the patient's sample. The results showed that
the copy number of the CFTR gene relative to the GAPDH
425D.L.M. Goh et al. / Journal of Cystic Fibrosis 6 (2007) 423–425gene control in the patient was not different from that of 5
normal control samples, hence ruling out a deletion of one
copy of CFTR as a cause of the observed mutation and
marker homozygosities.
3. Discussion
We have identified a novel splice site mutation in intron 6b
(1001+5 G→A) in the homozygous state in this patient. The
effect of this mutation was assessed using 3 splice predictor
programs (“Splice View”, “Splice Site Prediction by Neural
Network” and “Netgene2”). All independently predicted the
presence of a splice donor in the wild type sequence and did
not predict the presence of a splice donor in the mutant
sequence. Hence it is likely that, molecularly, this mutation
leads to aberrant splicing e.g. skipping of exon 6b, leading to
the production of less protein or an abnormal protein. This
would be in keeping with the clinical picture of having
CBAVD, a phenotype known to be caused by dysfunction of
the CFTR gene. It is also interesting to note that this patient
had pulmonary meliodosis, an infection that is seen in greater
incidence in individuals with cystic fibrosis [2].
In addition to this mutation, the patient had complete
homozygosity of all intragenic and flanking polymorphic
markers tested. This, coupled with parental nonconsanguinity
and the absence of any detectable deletion, strongly suggested
that he had uniparental isodisomy involving at least a part of
chromosome 7 that included the CFTR locus. While it is
possible that the patient could have had complete uniparental
isodisomy of chromosome 7, this was not experimentally
tested. Unfortunately, we could not determine the parental
origin of the isodisomy as both parents had declined to par-
ticipate in the study. It would be important to identify if
uniparental isodisomy is truly the cause as 1) affected in-
dividuals have an increased risk for other health problems such
as growth failure and developmental disability, 2) the risk of
recurrence for the parents would not necessarily be 25% and
may indeed be lower, and 3) there would be a need to test the
parents for the presence of other CFTR mutations that may
affect the risk of recurrence.
Mutations in the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) gene have been associated with cysticfibrosis, pancreatic insufficiency and congenital bilateral
absence of the vas deferens [3]. There is also suggestion that
mutations in this gene may be associated with other chronic
pulmonary diseases such as idiopathic bronchiectasis and
allergic bronchopulmonary aspergillosis. Our patient had a
history of BOOP, a clinical condition characterized by obli-
teration of the bronchial lumens by organizing connective and
infiltration of the alveoli by exudates and granulation tissue
[4]. Known causes of BOOP include previous radiation
therapy, infections, drugs, toxins, connective tissue diseases
and complications related to transplantation. The cause, how-
ever, cannot be identified in 50% of patients with BOOP. The
question remains if the association seen in our patient between
this novel CFTR mutation and BOOP was causal or merely
coincidental. This question can only be answered by further
research e.g. a case-control study of CFTRmutations inBOOP
and non-BOOP individuals.
In conclusion, we report the first case of homozygosity
for a novel CFTR splice site mutation in a patient with
congenital bilateral absence of the vas deferens (CBAVD).
The most likely origin of the homozygosity was uniparental
isodisomy of part or all of chromosome 7 that included the
CFTR and flanking genomic region. Further studies should
be done to ascertain if there is a causal relationship between
CFTR mutations and BOOP.
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